CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical
MWN-AI** Summary
Cardiac Biotech Solutions, Inc. (OTCID: CBSC) has announced a $375,000 purchase order from Noventis Medical, its exclusive distributor in Central America, for 2,500 MyCardia AT Cardiac Event Monitoring devices. Each unit is priced at $150, with 1,000 devices to be shipped immediately and the remaining 1,500 within 90 days. CEO Charles Martin emphasized that this purchase order underlines robust market demand for the MyCardia AT and signifies the inception of a sustainable long-term revenue model.
The company is expanding its business model beyond direct device sales by launching a recurring monthly rental program. This initiative will allow CBSC to earn consistent revenue by charging healthcare facilities for the use of each device, AWS Cloud-based monitoring software, and mobile applications. Revenue distribution favors the distributor, with CBSC earning one-third of the monthly fees, although pricing varies by country based on local healthcare economies and reimbursement structures.
The MyCardia AT platform combines lightweight, easy-to-use wearable technology with cloud connectivity, targeting improved cardiac monitoring solutions globally. With regulatory approvals already achieved in the U.S. and additional submissions pending in Canada and China, this agreement with Noventis Medical is a significant milestone for CBSC’s international expansion.
Noventis Medical, headquartered in Panama, is known for distributing advanced medical technologies throughout Central America, focusing on innovative solutions to enhance patient care. As they continue developing both their product lines and international presence, CBSC aims to significantly impact the cardiac monitoring market while providing value to healthcare partners and shareholders alike.
This announcement reflects CBSC’s strategic move towards establishing a steady revenue stream while addressing the growing demand for non-invasive cardiac monitoring solutions.
MWN-AI** Analysis
The recent announcement by Cardiac Biotech Solutions, Inc. (OTCID: CBSC) regarding a $375,000 purchase order from Noventis Medical marks a pivotal moment for the company, signaling strong market demand for its MyCardia AT Cardiac Event Monitoring devices. This initial order, coupled with the launch of a recurring revenue program, outlines a dual revenue model that enhances long-term sustainability and profitability.
From an investment perspective, this shift towards a recurring revenue model through device rentals is particularly noteworthy. CBSC's decision to diversify revenue streams will likely stabilize cash flow, providing consistent income that can mitigate risks associated with reliance solely on product sales. The integration of their monitoring technology with AWS Cloud-based solutions not only positions CBSC competitively but also aligns with global trends favoring digital health solutions.
Moreover, Noventis Medical's established distribution network in Central America can accelerate the uptake of MyCardia AT devices, potentially expanding market share in a region often underserved in innovative healthcare technologies. As regulatory approvals progress in key markets like Canada and China, CBSC is poised to scale its operations internationally.
However, potential investors should remain vigilant. The success of this ambitious strategy hinges on the company's ability to maintain product quality and support, as well as effective collaboration with distribution partners. Additionally, investors must consider existing market competition and the complex regulatory landscape that health tech companies often navigate.
In conclusion, while the recent announcement is a strong signal of growth potential, prudent investors should weigh both the promising revenue model and associated risks before committing capital. Continuous monitoring of CBSC's execution of its strategy will be essential in evaluating its long-term value proposition in the expanding market for non-invasive cardiac monitoring solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LAS VEGAS, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the receipt of an initial purchase order from Noventis Medical, its exclusive Central America distribution partner, for the supply of 2,500 MyCardia AT Cardiac Event Monitoring devices. The total order value is $375,000 USD based on a per-unit price of $150.
Under the terms of the agreement, 1,000 devices will be shipped immediately upon completion of production, with the remaining 1,500 units to be delivered within 90 days.
“This purchase order not only reinforces market demand for the MyCardia AT but also marks the beginning of a sustainable, long-term revenue model,” said Charles Martin, Chief Executive Officer of CBSC. “By combining device sales with recurring software-driven rental fees, we believe that we are positioned to deliver consistent value for both our healthcare partners and our shareholders.”
In addition to upfront device sales, CBSC has implemented a recurring monthly rental program to generate ongoing revenue from devices once deployed in hospitals and healthcare facilities. This program covers the use of each device, the AWS Cloud-based monitoring software, and patient-facing smartphone applications.
Revenue from the monthly rental program is shared between CBSC and its distributor partners, with CBSC receiving one-third of the monthly fee and the distributor retaining the balance. Pricing varies by country, reflecting regional healthcare economics and reimbursement practices.
The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and additional submissions progressing in Canada and China, this newest international agreement represents another significant milestone in CBSC’s mission to deliver state-of-the-art cardiac monitoring solutions worldwide.
About Noventis Medical
Noventis Medical, headquartered in Panama City, Panama, is a leading distributor of advanced medical technologies throughout Central America. The company specializes in introducing innovative healthcare solutions designed to improve patient outcomes across hospitals and clinical networks.
About Cardiac Biotech Solutions, Inc.
Cardiac Biotech Solutions, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Follow CBSC: X , Facebook , Instagram , LinkedIn , YouTube , and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
FAQ**
How does the recent purchase order from Noventis Medical solidify the long-term revenue model for CB Scientific Inc. CBSC as it seeks to expand the MyCardia AT Cardiac Event Monitoring product's market presence in Central America?
What strategies is CB Scientific Inc. CBSC implementing to navigate regional pricing variations and ensure successful implementation of its rental program in diverse healthcare markets?
In light of the recent agreement with Noventis Medical, what long-term projections can CB Scientific Inc. CBSC provide regarding the anticipated growth of its recurring revenue stream from device rentals?
How is CB Scientific Inc. CBSC addressing potential regulatory challenges as it seeks to expand its MyCardia AT platform's commercialization efforts in Canada and China after securing US clearance?
**MWN-AI FAQ is based on asking OpenAI questions about CB Scientific Inc (OTC: CBSC).
NASDAQ: CBSC
CBSC Trading
0.0% G/L:
$0.04 Last:
13,000 Volume:
$0.04 Open:
